NASDAQ:HALO

Halozyme Therapeutics Competitors

$42.77
+0.57 (+1.35 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$41.69
Now: $42.77
$42.98
50-Day Range
$39.51
MA: $43.80
$51.45
52-Week Range
$17.74
Now: $42.77
$56.40
Volume605,396 shs
Average Volume1.42 million shs
Market Capitalization$6.13 billion
P/E Ratio267.31
Dividend YieldN/A
Beta1.77

Competitors

Halozyme Therapeutics (NASDAQ:HALO) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying HALO stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Halozyme Therapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, dividends, analyst recommendations, profitability and earnings.

Insider & Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Amgen and Halozyme Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen0101402.58
Halozyme Therapeutics01902.90

Amgen currently has a consensus price target of $259.4091, suggesting a potential upside of 4.20%. Halozyme Therapeutics has a consensus price target of $42.9167, suggesting a potential upside of 0.34%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Halozyme Therapeutics.

Valuation & Earnings

This table compares Amgen and Halozyme Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.14$7.84 billion$14.8216.80
Halozyme Therapeutics$195.99 million31.27$-72,240,000.00($0.50)-85.54

Amgen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amgen and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Halozyme Therapeutics10.78%24.29%4.08%

Summary

Amgen beats Halozyme Therapeutics on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 0.1% of Gilead Sciences shares are held by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Gilead Sciences and Halozyme Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences191402.54
Halozyme Therapeutics01902.90

Gilead Sciences presently has a consensus price target of $97.2308, indicating a potential upside of 49.33%. Halozyme Therapeutics has a consensus price target of $42.9167, indicating a potential upside of 0.34%. Given Gilead Sciences' higher probable upside, equities analysts clearly believe Gilead Sciences is more favorable than Halozyme Therapeutics.

Valuation and Earnings

This table compares Gilead Sciences and Halozyme Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.65$5.39 billion$6.1410.60
Halozyme Therapeutics$195.99 million31.27$-72,240,000.00($0.50)-85.54

Gilead Sciences has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gilead Sciences and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Halozyme Therapeutics10.78%24.29%4.08%

Vertex Pharmaceuticals (NASDAQ:VRTX) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Vertex Pharmaceuticals and Halozyme Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Halozyme Therapeutics01902.90

Vertex Pharmaceuticals presently has a consensus price target of $293.1250, indicating a potential upside of 37.39%. Halozyme Therapeutics has a consensus price target of $42.9167, indicating a potential upside of 0.34%. Given Vertex Pharmaceuticals' higher probable upside, equities analysts clearly believe Vertex Pharmaceuticals is more favorable than Halozyme Therapeutics.

Valuation and Earnings

This table compares Vertex Pharmaceuticals and Halozyme Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.32$1.18 billion$4.2949.73
Halozyme Therapeutics$195.99 million31.27$-72,240,000.00($0.50)-85.54

Vertex Pharmaceuticals has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vertex Pharmaceuticals and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Halozyme Therapeutics10.78%24.29%4.08%

Summary

Vertex Pharmaceuticals beats Halozyme Therapeutics on 9 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Insider and Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Regeneron Pharmaceuticals and Halozyme Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Halozyme Therapeutics01902.90

Regeneron Pharmaceuticals presently has a consensus price target of $637.2083, indicating a potential upside of 34.10%. Halozyme Therapeutics has a consensus price target of $42.9167, indicating a potential upside of 0.34%. Given Regeneron Pharmaceuticals' higher probable upside, equities analysts clearly believe Regeneron Pharmaceuticals is more favorable than Halozyme Therapeutics.

Valuation and Earnings

This table compares Regeneron Pharmaceuticals and Halozyme Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.47$2.12 billion$21.4722.13
Halozyme Therapeutics$195.99 million31.27$-72,240,000.00($0.50)-85.54

Regeneron Pharmaceuticals has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regeneron Pharmaceuticals and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Halozyme Therapeutics10.78%24.29%4.08%

Summary

Regeneron Pharmaceuticals beats Halozyme Therapeutics on 10 of the 15 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Halozyme Therapeutics (NASDAQ:HALO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Valuation and Earnings

This table compares Biogen and Halozyme Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.84$5.89 billion$33.577.99
Halozyme Therapeutics$195.99 million31.27$-72,240,000.00($0.50)-85.54

Biogen has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

83.5% of Biogen shares are held by institutional investors. Comparatively, 98.5% of Halozyme Therapeutics shares are held by institutional investors. 0.5% of Biogen shares are held by insiders. Comparatively, 2.6% of Halozyme Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Biogen and Halozyme Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5141202.23
Halozyme Therapeutics01902.90

Biogen presently has a consensus price target of $303.5517, indicating a potential upside of 13.19%. Halozyme Therapeutics has a consensus price target of $42.9167, indicating a potential upside of 0.34%. Given Biogen's higher probable upside, equities analysts clearly believe Biogen is more favorable than Halozyme Therapeutics.

Risk and Volatility

Biogen has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Profitability

This table compares Biogen and Halozyme Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Halozyme Therapeutics10.78%24.29%4.08%

Summary

Biogen beats Halozyme Therapeutics on 8 of the 14 factors compared between the two stocks.

Halozyme Therapeutics (NASDAQ:HALO) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, valuation, earnings, analyst recommendations, risk and institutional ownership.

Valuation & Earnings

This table compares Halozyme Therapeutics and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$195.99 million31.27$-72,240,000.00($0.50)-85.54
Alexion Pharmaceuticals$4.99 billion6.83$2.40 billion$9.7415.91

Alexion Pharmaceuticals has higher revenue and earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

98.5% of Halozyme Therapeutics shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 2.6% of Halozyme Therapeutics shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Halozyme Therapeutics and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Halozyme Therapeutics01902.90
Alexion Pharmaceuticals017512.30

Halozyme Therapeutics presently has a consensus target price of $42.9167, indicating a potential upside of 0.34%. Alexion Pharmaceuticals has a consensus target price of $153.8636, indicating a potential downside of 0.74%. Given Halozyme Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Halozyme Therapeutics is more favorable than Alexion Pharmaceuticals.

Volatility & Risk

Halozyme Therapeutics has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares Halozyme Therapeutics and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Halozyme Therapeutics10.78%24.29%4.08%
Alexion Pharmaceuticals16.32%23.16%14.76%

Summary

Halozyme Therapeutics beats Alexion Pharmaceuticals on 8 of the 15 factors compared between the two stocks.


Halozyme Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$248.95+0.8%$143.35 billion$23.36 billion20.08Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.11+0.1%$81.98 billion$22.45 billion67.12
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$213.35+1.4%$55.46 billion$4.16 billion26.94Insider Selling
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$475.17+0.3%$50.91 billion$7.86 billion17.37News Coverage
Biogen logo
BIIB
Biogen
1.9$268.17+0.9%$40.85 billion$14.38 billion8.88
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$155.01+0.3%$34.08 billion$4.99 billion36.22
Seagen logo
SGEN
Seagen
1.7$142.85+1.1%$25.90 billion$916.71 million56.24Insider Selling
News Coverage
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.54+2.4%$21.23 billion$876.29 million-56.81Gap Down
Incyte logo
INCY
Incyte
1.9$79.96+1.1%$17.58 billion$2.16 billion-50.93News Coverage
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.23+3.1%$16.22 billion$219.75 million-17.65News Coverage
Gap Down
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$77.07+1.5%$14.01 billion$1.70 billion17.64Insider Selling
News Coverage
Novavax logo
NVAX
Novavax
1.6$179.74+1.9%$13.28 billion$18.66 million-34.43Insider Selling
Gap Up
Repligen logo
RGEN
Repligen
1.5$206.10+0.9%$11.29 billion$270.24 million251.34News Coverage
United Therapeutics logo
UTHR
United Therapeutics
1.5$203.36+1.3%$9.06 billion$1.45 billion19.24Analyst Report
Analyst Revision
News Coverage
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.35+0.7%$8.77 billion$788.10 million100.38Analyst Downgrade
Exelixis logo
EXEL
Exelixis
1.9$23.12+1.0%$7.21 billion$967.78 million48.17
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$42.36+0.8%$5.97 billion$1.12 billion88.25
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$77.35+1.6%$4.12 billion$1.11 billion24.87Analyst Report
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.5$66.29+0.3%$4.00 billion$806.43 million-9.39
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$49.41+0.6%$3.44 billion$36.13 million-73.75Unusual Options Activity
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$19.02+0.2%$3.03 billion$1.17 billion-41.35Unusual Options Activity
OPKO Health logo
OPK
OPKO Health
1.9$4.18+2.2%$2.80 billion$901.90 million-23.22
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$153.44+1.4%$2.55 billion$120.28 million-154.99Analyst Upgrade
News Coverage
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.19+0.9%$2.43 billion$182.24 million-7.99News Coverage
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$28.16+1.1%$2.12 billion$638.60 million-10.83
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02+0.4%$1.88 billionN/A-10.57
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$10.21+1.9%$1.81 billion$48.83 million-13.43
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19+1.5%$1.64 billion$428.41 million14.77
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02+2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Gap Down
Codexis logo
CDXS
Codexis
1.1$24.00+2.6%$1.55 billion$68.46 million-68.57Insider Selling
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56+3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
News Coverage
Gap Down
Innoviva logo
INVA
Innoviva
1.4$11.70+1.6%$1.19 billion$261.02 million5.97
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07+1.0%$1.14 billion$35.22 million-7.35
Curis logo
CRIS
Curis
1.3$11.50+2.9%$1.05 billion$10 million-14.02Gap Down
MannKind logo
MNKD
MannKind
1.4$4.24+1.9%$1.05 billion$63.04 million-20.19News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.25+2.2%$891.85 million$227.19 million45.14Analyst Upgrade
Gap Down
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$23.19+2.0%$842.45 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$20.71+1.4%$820.43 million$3.57 million-9.29Analyst Upgrade
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.37+1.1%$775.18 million$322.07 million-5.11
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$22.17+5.3%$731.97 million$252 million-2.27Gap Down
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.32+2.1%$714.48 million$150,000.00-4.74Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$6.23+5.6%$651.22 million$143.01 million-1.19Gap Down
Agenus logo
AGEN
Agenus
1.6$2.79+0.0%$570.05 million$150.05 million-2.56
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.26+1.8%$554.59 million$59.29 million-21.73
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$5.44+10.3%$516.29 million$36.63 million-6.40Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Gap Up
Verastem logo
VSTM
Verastem
1.1$2.76+1.8%$473.80 million$17.46 million-1.96Analyst Report
Analyst Revision
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.07+3.9%$471.95 million$109.33 million-2.26Gap Down
Geron logo
GERN
Geron
1.4$1.48+2.7%$471.43 million$460,000.00-4.23Analyst Report
News Coverage
Gap Down
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.23+0.4%$461.31 million$22.27 million-4.03Analyst Report
Insider Buying
High Trading Volume
Unusual Options Activity
Analyst Revision
XOMA logo
XOMA
XOMA
1.3$38.99+0.8%$438.75 million$18.37 million-35.13Analyst Upgrade
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.